1. Li L, Sun Q. Renal transplantation in China: ten years of experience at Nanjing Jinling Hospital. In: Clinical transplants 2006. Los Angeles (CA): Terasaki Research Institute, 2006.
2. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection: acute and chronic studies. Contrib Nephrol 2008;159:122–134.
3. Miano TA, Flesch JD, Feng R, et al. Early tacrolimus concentrations after lung transplant are predicted by combined clinical and genetic factors and associated with acute kidney injury. Clin Pharmacol Ther 2020;107:462–470.
4. Braithwaite HE, Darley DR, Brett J, Day RO, Carland JE. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: a systematic review. Transplant Rev (Orlando) 2021;35:100610.
5. Lim SW, Shin YJ, Luo K, et al. Effect of Klotho on autophagy clearance in tacrolimus-induced renal injury. FASEB J 2019;33:2694–2706.
6. Lim SW, Jin L, Piao SG, Chung BH, Yang CW. Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury. Lab Invest 2015;95:1174–1185.
7. Lee D, Lee DS, Jung K, et al. Protective effect of ginsenoside Rb1 against tacrolimus-induced apoptosis in renal proximal tubular LLC-PK1 cells. J Ginseng Res 2018;42:75–80.
8. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998;18:389–418.
9. Pilat N, Mahr B, Gattringer M, Baranyi U, Wekerle T. CTLA4Ig improves murine iTreg induction via TGFβ and suppressor function in vitro. J Immunol Res 2018;2018:2484825.
10. Jaiswal SR, Bhakuni P, Aiyer HM, Soni M, Bansal S, Chakrabarti S. CTLA4Ig in an extended schedule along with sirolimus improves outcome with a distinct pattern of immune reconstitution following post-transplantation cyclophosphamide-based haploidentical transplantation for hemoglobinopathies. Biol Blood Marrow Transplant 2020;26:1469–1476.
11. Kumar D, LeCorchick S, Gupta G. Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants. Front Med (Lausanne) 2017;4:60.
12. Jin L, Lim SW, Jin J, et al. Effect of conversion to CTLA4Ig on tacrolimus-induced diabetic rats. Transplantation 2018;102:e137–e146.
13. Wang Y, Lin Y, Wang L, et al. TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K/AKT/ FoxO3a signaling pathway in Alzheimer’s disease mice. Aging (Albany NY) 2020;12:20862–20879.
14. Zhang X, Wang L, Peng L, et al. Dihydromyricetin protects HUVECs of oxidative damage induced by sodium nitroprusside through activating PI3K/Akt/FoxO3a signalling pathway. J Cell Mol Med 2019;23:4829–4838.
15. Yoon HE, Kim SJ, Kim SJ, Chung S, Shin SJ. Tempol attenuates renal fibrosis in mice with unilateral ureteral obstruction: the role of PI3K-Akt-FoxO3a signaling. J Korean Med Sci 2014;29:230–237.
16. Zhao S, Wang L, Zhang C, et al. Inhibitor of growth 3 induces cell death by regulating cell proliferation, apoptosis and cell cycle arrest by blocking the PI3K/AKT pathway. Cancer Gene Ther 2018;25:240–247.
17. Jin L, Lim SW, Doh KC, et al. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats. PLoS One 2014;9:e100798.
18. Chevalier RL, Goyal S, Kim A, Chang AY, Landau D, LeRoith D. Renal tubulointerstitial injury from ureteral obstruction in the neonatal rat is attenuated by IGF-1. Kidney Int 2000;57:882–890.
19. Haffner D, Grund A, Leifheit-Nestler M. Renal effects of growth hormone in health and in kidney disease. Pediatr Nephrol 2021;36:2511–2530.
20. Fu R, Tajima S, Shigematsu T, et al. Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. Toxicol Lett 2021;341:43–50.
21. Jiang YJ, Cui S, Luo K, et al. Nicotine exacerbates tacrolimus-induced renal injury by programmed cell death. Korean J Intern Med 2021;36:1437–1449.
22. Jin J, Jin L, Luo K, Lim SW, Chung BH, Yang CW. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant 2017;17:2601–2616.
23. Yang CC, Sung PH, Chiang JY, et al. Combined tacrolimus and melatonin effectively protected kidney against acute ischemia-reperfusion injury. FASEB J 2021;35:e21661.
24. Piao SG, Lim SW, Doh KC, et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation 2014;98:22–28.
25. Chen Y, Feng X, Hu X, et al. Dexmedetomidine ameliorates acute stress-induced kidney injury by attenuating oxidative stress and apoptosis through inhibition of the ROS/JNK signaling pathway. Oxid Med Cell Longev 2018;2018:4035310.
26. García-Pérez E, Ryu D, Kim HY, Kim HD, Lee HJ. Human proximal tubule epithelial cells (HK-2) as a sensitive in vitro system for ochratoxin a induced oxidative stress. Toxins (Basel) 2021;13:787.
27. Wang YL, Lee YH, Hsu YH, et al. The kidney-related effects of polystyrene microplastics on human kidney proximal tubular epithelial cells HK-2 and male C57BL/6 mice. Environ Health Perspect 2021;129:57003.
28. Gao P, Du X, Liu L, et al. Astragaloside IV alleviates tacrolimus-induced chronic nephrotoxicity via p62-Keap1-Nrf2 pathway. Front Pharmacol 2021;11:610102.
29. Zheng HL, Zhang HY, Zhu CL, et al. L-Carnitine protects against tacrolimus-induced renal injury by attenuating programmed cell death via PI3K/AKT/PTEN signaling. Acta Pharmacol Sin 2021;42:77–87.
30. Guerrieri D, Ambrosi NG, Romeo H, et al. Secretory leukocyte proteinase inhibitor protects acute kidney injury through immune and non-immune pathways. Shock 2021;56:1019–1027.
31. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011;1813:1938–1945.
32. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829–1833.
33. Yamamoto M, Clark JD, Pastor JV, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005;280:38029–38034.
34. Unger RH. Klotho-induced insulin resistance: a blessing in disguise? Nat Med 2006;12:56–57.
35. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 2008;105:2622–2627.
36. Lim SW, Jin L, Luo K, et al. Klotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stress. Cell Death Dis 2017;8:e2972.
37. Reyes HD, Carlson MJ, Devor EJ, et al. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. Gynecol Oncol 2016;140:152–160.
38. Du M, Wang Q, Li W, et al. Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo. Biochem Biophys Res Commun 2016;471:416–422.
39. Li W, Wang Q, Du M, et al. Effects of overexpressing FoxO1 on apoptosis in glomeruli of diabetic mice and in podocytes cultured in high glucose medium. Biochem Biophys Res Commun 2016;478:612–617.
40. Fallarino F, Bianchi R, Orabona C, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004;200:1051–1062.
41. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005;15:316–328.
42. Graille M, Wild P, Sauvain JJ, Hemmendinger M, Guseva Canu I, Hopf NB. Urinary 8-OHdG as a biomarker for oxidative stress: a systematic literature review and meta-analysis. Int J Mol Sci 2020;21:3743.
43. Soulage CO, Pelletier CC, Florens N, et al. Two toxic lipid aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), accumulate in patients with chronic kidney disease. Toxins (Basel) 2020;12:567.
44. Saeki T, Ichiba M, Tanabe N, et al. Expression of oxidative stress-related molecules in circulating leukocytes and urine in patients with chronic viral hepatitis. Liver Int 2006;26:157–165.
45. Homma T, Fujii J. Application of glutathione as anti-oxidative and anti-aging drugs. Curr Drug Metab 2015;16:560–571.
46. Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic Biol Med 2016;95:27–42.
47. Kim JL, Reader BF, Dumond C, et al. Pegylated-catalase is protective in lung ischemic injury and oxidative stress. Ann Thorac Surg 2021;111:1019–1027.
48. Tahir M, Rehman MYA, Malik RN. Heavy metal-associated oxidative stress and glutathione S-transferase polymorphisms among E-waste workers in Pakistan. Environ Geochem Health 2021;43:4441–4458.
49. Qin G, Zhou Y, Guo F, et al. Overexpression of the FoxO1 ameliorates mesangial cell dysfunction in male diabetic rats. Mol Endocrinol 2015;29:1080–1091.
50. Dávila D, Torres-Aleman I. Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell 2008;19:2014–2025.
51. Genis L, Dávila D, Fernandez S, Pozo-Rodrigálvarez A, Martínez-Murillo R, Torres-Aleman I. Astrocytes require insulin-like growth factor I to protect neurons against oxidative injury. F1000Res 2014;3:28.
52. Lehtinen MK, Yuan Z, Boag PR, et al. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 2006;125:987–1001.
留言 (0)